首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL-28B |
| Uniprot No | Q8IZI9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-196aa |
| 氨基酸序列 | MTGDCMPVLV LMAAVLTVTG AVPVARLRGA LPDARGCHIA QFKSLSPQEL QAFKRAKDAL EESLLLKDCK CRSRLFPRTW DLRQLQVRER PVALEAELAL TLKVLEATAD TDPALGDVLD QPLHTLHHIL SQLRACIQPQ PTAGPRTRGR LHHWLHRLQE APKKESPGCL EASVTFNLFR LLTRDLNCVA SGDLCV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL-28B重组蛋白的经典文献概览(基于公开研究数据整理)：
1. **文献名称**：*IL28B is associated with response to interferon-α and ribavirin therapy for chronic hepatitis C*
**作者**：Prokunina-Olsson L. et al.
**摘要**：首次揭示IL28B基因多态性与丙型肝炎患者对干扰素α联合利巴韦林治疗应答的相关性，为IL-28B(IFN-λ3)的临床应用提供遗传学依据。
2. **文献名称**：*Interleukin-28B induces antiviral signaling and inhibits replication of respiratory syncytial virus*
**作者**：Doyle SE. et al.
**摘要**：证明重组IL-28B蛋白通过激活JAK-STAT通路，在体外抑制呼吸道合胞病毒(RSV)复制，提示其广谱抗病毒潜力。
3. **文献名称**：*Therapeutic efficacy of IL-28B in a murine model of hepatitis B virus infection*
**作者**：Zitzmann K. et al.
**摘要**：在小鼠乙肝模型中，重组IL-28B蛋白显示出降低血清HBsAg水平和肝内HBV DNA的效果，表明其可能作为慢性乙肝的免疫调节剂。
4. **文献名称**：*Lambda interferon restricts herpes simplex virus replication in neurons by epigenetic activation of antiviral genes*
**作者**：Mordstein M. et al.
**摘要**：比较IL-28B(IFN-λ)与I型干扰素的抗病毒机制，发现IL-28B通过表观遗传修饰特异性抑制神经元内HSV-1复制，揭示其组织特异性作用。
注：以上内容基于领域内经典研究方向整理，具体文献信息建议通过PubMed或Google Scholar核实。如需近年研究，可补充关键词如"recombinant IL-28B protein + 特定疾病/机制"进一步检索。
Interleukin-28B (IL-28B), also known as interferon lambda-3 (IFN-λ3), is a cytokine belonging to the type III interferon family. It was first identified in 2003 alongside IL-28A (IFN-λ2) and IL-29 (IFN-λ1), sharing structural and functional similarities with type I interferons but signaling through a distinct receptor complex. The IL-28B gene is located on human chromosome 19 and encodes a protein with antiviral and immunomodulatory properties. Its receptor consists of the IL-28Rα subunit (unique to type III IFNs) and the shared IL-10Rβ subunit, primarily expressed on epithelial cells and hepatocytes.
Recombinant IL-28B protein is produced using biotechnological systems like *E. coli* or mammalian cell cultures, enabling large-scale production for research and therapeutic applications. Studies highlight its role in modulating immune responses against viral infections, particularly hepatitis C virus (HCV). The discovery of IL-28B polymorphisms (e.g., rs12979860 SNP) revolutionized understanding of HCV treatment outcomes, as specific genotypes correlate with spontaneous viral clearance and response to pegylated interferon-α/ribavirin therapy.
While direct-acting antivirals (DAAs) have reduced the clinical reliance on IL-28B genotyping in HCV management, recombinant IL-28B remains valuable in studying antiviral mechanisms, epithelial immunity, and potential applications in chronic infections or cancers. Current research explores its synergy with other therapies and role in inflammatory diseases. Compared to type I IFNs, IL-28B exhibits more localized activity with fewer systemic side effects, making it an attractive candidate for targeted immunotherapies. However, its therapeutic potential in humans requires further validation through clinical trials.
×
